• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cdk2 增强了细胞内 S 期检查点,抵消了由 DNA 损伤诱导的细胞周期退出。

Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage.

机构信息

IGMM, CNRS, Univ. Montpellier, Montpellier, France.

Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015, Lausanne, Switzerland.

出版信息

Sci Rep. 2017 Oct 18;7(1):13429. doi: 10.1038/s41598-017-12868-5.

DOI:10.1038/s41598-017-12868-5
PMID:29044141
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5647392/
Abstract

Although cyclin-dependent kinase 2 (Cdk2) controls the G1/S transition and promotes DNA replication, it is dispensable for cell cycle progression due to redundancy with Cdk1. Yet Cdk2 also has non-redundant functions that can be revealed in certain genetic backgrounds and it was reported to promote the G2/M DNA damage response checkpoint in TP53 (p53)-deficient cancer cells. However, in p53-proficient cells subjected to DNA damage, Cdk2 is inactivated by the CDK inhibitor p21. We therefore investigated whether Cdk2 differentially affects checkpoint responses in p53-proficient and deficient cell lines. We show that, independently of p53 status, Cdk2 stimulates the ATR/Chk1 pathway and is required for an efficient DNA replication checkpoint response. In contrast, Cdk2 is not required for a sustained DNA damage response and G2 arrest. Rather, eliminating Cdk2 delays S/G2 progression after DNA damage and accelerates appearance of early markers of cell cycle exit. Notably, Cdk2 knockdown leads to down-regulation of Cdk6, which we show is a non-redundant pRb kinase whose elimination compromises cell cycle progression. Our data reinforce the notion that Cdk2 is a key p21 target in the DNA damage response whose inactivation promotes exit from the cell cycle in G2.

摘要

虽然细胞周期蛋白依赖性激酶 2(Cdk2)控制 G1/S 期转换并促进 DNA 复制,但由于与 Cdk1 的冗余,它对于细胞周期进程不是必需的。然而,Cdk2 也具有非冗余功能,这些功能可以在某些遗传背景下显现出来,并且据报道,它可以促进 TP53(p53)缺陷型癌细胞中的 G2/M DNA 损伤反应检查点。然而,在 p53 功能正常的细胞中受到 DNA 损伤时,CDK 抑制剂 p21 使 Cdk2 失活。因此,我们研究了 Cdk2 是否会对 p53 功能正常和缺陷的细胞系中的检查点反应产生不同的影响。我们表明,独立于 p53 状态,Cdk2 可刺激 ATR/Chk1 途径,并且是有效的 DNA 复制检查点反应所必需的。相比之下,Cdk2 对于持续的 DNA 损伤反应和 G2 期阻滞不是必需的。相反,消除 Cdk2 会延迟 DNA 损伤后 S/G2 期的进展,并加速细胞周期退出的早期标志物的出现。值得注意的是,Cdk2 的敲低导致 Cdk6 的下调,我们表明 Cdk6 是一种非冗余的 pRb 激酶,其消除会损害细胞周期进程。我们的数据强化了这样一种观点,即 Cdk2 是 DNA 损伤反应中 p21 的关键靶标,其失活可促进 G2 期细胞周期退出。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/c0c0a7b3bea8/41598_2017_12868_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/f8b547db701d/41598_2017_12868_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/fc4634155419/41598_2017_12868_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/187baa65f1c2/41598_2017_12868_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/72a44fd676fa/41598_2017_12868_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/c0c0a7b3bea8/41598_2017_12868_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/f8b547db701d/41598_2017_12868_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/fc4634155419/41598_2017_12868_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/187baa65f1c2/41598_2017_12868_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/72a44fd676fa/41598_2017_12868_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1620/5647392/c0c0a7b3bea8/41598_2017_12868_Fig5_HTML.jpg

相似文献

1
Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage.Cdk2 增强了细胞内 S 期检查点,抵消了由 DNA 损伤诱导的细胞周期退出。
Sci Rep. 2017 Oct 18;7(1):13429. doi: 10.1038/s41598-017-12868-5.
2
Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.当 ATM/p53/p21 通路功能正常时,Chk1 在应对持续的 DNA 损伤导致的 G2 期阻滞中是可有可无的。
Oncogene. 2011 Oct 13;30(41):4261-74. doi: 10.1038/onc.2011.135. Epub 2011 May 2.
3
A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.由于S期CDK2激活,一部分癌细胞系对Chk1抑制剂MK-8776单药治疗极为敏感。
Oncotarget. 2016 Jan 12;7(2):1380-94. doi: 10.18632/oncotarget.6364.
4
Reciprocal regulation of p21 and Chk1 controls the cyclin D1-RB pathway to mediate senescence onset after G2 arrest.p21和Chk1的相互调节控制细胞周期蛋白D1-RB途径,以介导G2期阻滞后的衰老起始。
J Cell Sci. 2022 Apr 15;135(8). doi: 10.1242/jcs.259114. Epub 2022 Apr 28.
5
Cdk2 is required for p53-independent G2/M checkpoint control.Cdk2 对于 p53 非依赖性 G2/M 检验点控制是必需的。
PLoS Genet. 2010 Feb 26;6(2):e1000863. doi: 10.1371/journal.pgen.1000863.
6
CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.CDK4 抑制在多柔比星诱导的 DNA 损伤情况下恢复 MYCN 扩增神经母细胞瘤细胞的 G1-S 期阻滞。
Cell Cycle. 2013 Apr 1;12(7):1091-104. doi: 10.4161/cc.24091. Epub 2013 Mar 5.
7
An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells.CDK2 在人胚胎干细胞 G1 期到 S 期检验点激活和 DNA 损伤反应中的重要作用。
Stem Cells. 2011 Apr;29(4):651-9. doi: 10.1002/stem.620.
8
The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.顺式铂类化合物及其非交叉耐药铂(IV)类似物对 S 和 G2 检验点反应对 G1 期阻滞保真度的影响的比较。
Gynecol Oncol. 2011 Aug;122(2):402-9. doi: 10.1016/j.ygyno.2011.04.034. Epub 2011 May 18.
9
Nuclear translocation of Cyclin B1 marks the restriction point for terminal cell cycle exit in G2 phase.细胞周期蛋白B1的核转位标志着G2期终末细胞周期退出的限制点。
Cell Cycle. 2014;13(17):2733-43. doi: 10.4161/15384101.2015.945831.
10
Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.p53和ATM基因产物在G1/S和S期检查点调控中的要求。
Oncogene. 1998 Feb 12;16(6):721-36. doi: 10.1038/sj.onc.1201793.

引用本文的文献

1
Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E).新型CDK2/CDK9抑制剂法曲利布靶向细胞存活和DNA损伤途径,并与恩考芬尼在携带BRAF(V600E)的人结肠癌细胞中发挥协同作用。
Oncogenesis. 2025 Aug 6;14(1):27. doi: 10.1038/s41389-025-00574-1.
2
Molecular mechanisms underlying the potential anticancer activity of hexane fraction in HCT116 cancer cells.己烷组分在HCT116癌细胞中潜在抗癌活性的分子机制。
3 Biotech. 2025 Aug;15(8):257. doi: 10.1007/s13205-025-04423-1. Epub 2025 Jul 15.
3
Differentiated muscle cells of salamander Pleurodeles waltl re-enter the cell cycle.

本文引用的文献

1
Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels.细胞周期调控解释了 Ki-67 表达水平的可变性。
Cancer Res. 2017 May 15;77(10):2722-2734. doi: 10.1158/0008-5472.CAN-16-0707. Epub 2017 Mar 10.
2
Cell cycle proteins as promising targets in cancer therapy.细胞周期蛋白作为癌症治疗中有前景的靶点。
Nat Rev Cancer. 2017 Jan 27;17(2):93-115. doi: 10.1038/nrc.2016.138.
3
A CDK2 activity signature predicts outcome in CDK2-low cancers.CDK2活性特征可预测CDK2低表达癌症的预后。
蝾螈(Pleurodeles waltl)的分化肌肉细胞重新进入细胞周期。
Histochem Cell Biol. 2025 Apr 17;163(1):46. doi: 10.1007/s00418-025-02377-2.
4
A comprehensive apoptotic assessment of niloticin in cervical cancer cells: a tirucallane-type triterpenoid from (Wall.) Parker.尼罗替辛对宫颈癌细胞的全面凋亡评估:一种来自(Wall.)Parker的四环三萜类化合物。
RSC Med Chem. 2024 Aug 8;15(10):3444-59. doi: 10.1039/d4md00318g.
5
GRK2-mediated AKT activation controls cell cycle progression and G2 checkpoint in a p53-dependent manner.GRK2介导的AKT激活以p53依赖的方式控制细胞周期进程和G2期检查点。
Cell Death Discov. 2024 Aug 29;10(1):385. doi: 10.1038/s41420-024-02143-8.
6
LncRNA PTENP1/miR-21/PTEN Axis Modulates EMT and Drug Resistance in Cancer: Dynamic Boolean Modeling for Cell Fates in DNA Damage Response.LncRNA PTENP1/miR-21/PTEN 轴调控癌症中的 EMT 和耐药性:DNA 损伤反应中细胞命运的动态布尔建模。
Int J Mol Sci. 2024 Jul 29;25(15):8264. doi: 10.3390/ijms25158264.
7
Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers.细胞周期蛋白依赖性激酶 2(CDK2)在导管原位癌和早期浸润性乳腺癌中的临床病理意义。
Int J Mol Sci. 2024 May 6;25(9):5053. doi: 10.3390/ijms25095053.
8
miR-425-5p Regulates Proliferation of Bovine Mammary Epithelial Cells by Targeting .miR-425-5p 通过靶向. 调节牛乳腺上皮细胞的增殖。
Genes (Basel). 2024 Jan 28;15(2):174. doi: 10.3390/genes15020174.
9
GSE1 links the HDAC1/CoREST co-repressor complex to DNA damage.GSE1 将 HDAC1/CoREST 共抑制复合物与 DNA 损伤联系起来。
Nucleic Acids Res. 2023 Nov 27;51(21):11748-11769. doi: 10.1093/nar/gkad911.
10
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer.癌症中 G0 细胞周期停滞的基因组特征和治疗意义。
Genome Biol. 2023 May 23;24(1):128. doi: 10.1186/s13059-023-02963-4.
Oncogene. 2017 May 4;36(18):2491-2502. doi: 10.1038/onc.2016.409. Epub 2016 Nov 7.
4
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.获得性CDK6扩增促进乳腺癌对CDK4/6抑制剂的耐药性以及雌激素受体信号传导和依赖性的丧失。
Oncogene. 2017 Apr 20;36(16):2255-2264. doi: 10.1038/onc.2016.379. Epub 2016 Oct 17.
5
Hypersensitivity to DNA damage in antephase as a safeguard for genome stability.前期 DNA 损伤超敏反应作为基因组稳定性的保障。
Nat Commun. 2016 Aug 26;7:12618. doi: 10.1038/ncomms12618.
6
Paradoxical roles of cyclin D1 in DNA stability.细胞周期蛋白 D1 在 DNA 稳定性中的矛盾作用。
DNA Repair (Amst). 2016 Jun;42:56-62. doi: 10.1016/j.dnarep.2016.04.011. Epub 2016 Apr 28.
7
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.通过dNTP饥饿抑制WEE1可选择性杀死组蛋白H3K36me3缺陷型癌症。
Cancer Cell. 2015 Nov 9;28(5):557-568. doi: 10.1016/j.ccell.2015.09.015.
8
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.CDK6 综述:回顾过去,展望未来:从细胞周期调控到转录调控。
Oncogene. 2016 Jun 16;35(24):3083-91. doi: 10.1038/onc.2015.407. Epub 2015 Oct 26.
9
Senescence from G2 arrest, revisited.重新审视G2期阻滞导致的衰老。
Cell Cycle. 2015;14(3):297-304. doi: 10.1080/15384101.2014.1000134.
10
Nuclear translocation of Cyclin B1 marks the restriction point for terminal cell cycle exit in G2 phase.细胞周期蛋白B1的核转位标志着G2期终末细胞周期退出的限制点。
Cell Cycle. 2014;13(17):2733-43. doi: 10.4161/15384101.2015.945831.